- One reason that cancer patients can have a poor response to a cancer therapy is due to the cancer cell’s ability to evade the therapy, through a variety of means including mutations to their own genome. A group of researchers from Italy explored the way colorectal cancer cells increase the rate of DNA mutations to evade targeted therapy. The study was published in Science.
- The first attempt in the United States to use CRISPR gene editing technology for cancer management was reported this week. A phase I trial showed safety and feasibility of using this technology in cancer immunotherapy and a potential for its further exploration in cancer management. The study will be presented next month at a meeting of the American Society of Hematology.
- Researchers from the University of Nottingham developed a blood test using protein microarray screening technology which can detect breast cancer “up to five years before there are any clinical signs of it.” This was reported at 2019 NCRI Cancer Conference.
- Researchers at the Johns Hopkins University found evidence that tumor cells spread increases when they are suffering from oxygen deprivation, or hypoxia. The study was published in October in Nature Communications.
Register now for “Open Access : Clarifying Facts & Busting Myths with Springer Nature Editors”
Join us for the next event in our Advancing Authorship series.
When: Thursday, December 5, 12:00 PM -1:30 PM
Where: Rockefeller Research Labs Building, Room 116, 430 E 67 Street
Register now to save your seat!
Join us for a deep dive into open access with the largest open access publisher (Springer Nature) and two distinguished MSK authors. We’ll help you separate fact from fiction when it comes to different publishing models.
We offer complimentary registration and refreshments.
Speakers:
- Kevin Pang, PhD, Associate Editor, Genome Biology, Springer Nature
- Brooke LaFlamme, PhD, Chief Editor, Communications Biology, Nature
- Jan Grimm, MD, PhD, Member/Attending/Professor, Molecular Pharmacology Program and Department of Radiology, MSK
- Kayvan R. Keshari, PhD, Attending/Professor, Molecular Pharmacology Program & Department of Radiology, MSK
Register now to save your seat!
Gaining InSight into Patient Symptoms
A recent article in Harvard Business Review features MSK’s new InSight Care program. It is written by three members of the MSK team working on the program, Dr. Robert Daly, Abigail Baldwin-Medsker, and Wendy Perchick.
Left to right: Dr. Robert Daly, assistant attending, Thoracic Oncology Service, and clinical lead, InSight Care Program. Abigail Baldwin-Medsker, digital accelerator product manager, nurse leader for outpatient services, and clinical lead, InSight Care Program. Wendy Perchick, senior vice president of strategy and innovation.
The goal of InSight Care is to predict each chemotherapy patient’s risk of needing care between treatments through an analytical model based on previous patient observations, a patient-reported symptom survey, and a team of nurses and advanced practice professionals who use the platform to monitor and communicate with patients remotely.
Of the 106 patients in the program’s pilot, 14 (13%) required acute care at MSK, compared to 32% of similar patients not participating in the program. Patients report that they appreciate the quick, 24/7 care InSight Care provides them without their having to leave home. The authors plan to expand the pilot and continue to refine the tool.